Document Detail


Drug-induced graves disease from CTLA-4 receptor suppression.
MedLine Citation:
PMID:  21242854     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Monoclonal antibody, ipilimumab, useful for treatment of metastatic melanoma, blocks CTLA-4 mediated T-cell suppression and can also cause a Graves ophthalmopathy like syndrome. Epidemiologic study has linked variant polymorphisms of CTLA-4 receptor gene to the presence of thyroid eye disease. The combination of these observations suggests CTLA-4 mediated T-cell functions are important to the pathogenesis of thyroid-associated eye disease.
Authors:
Gary Borodic; David M Hinkle; Yihong Cia
Related Documents :
15327734 - Factor structure of the cerad neuropsychological battery.
17599704 - Brain mapping as a tool to study neurodegeneration.
18272374 - Association study of the gab2 gene with the risk of developing alzheimer's disease.
1587974 - The clock test: a sensitive measure to differentiate normal elderly from those with alz...
8546514 - Abrupt aggravation of atrioventricular block and syncope in hypertrophic cardiomyopathy.
1771154 - Treatment of parkinson's disease with electroconvulsive therapy.
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Ophthalmic plastic and reconstructive surgery     Volume:  27     ISSN:  1537-2677     ISO Abbreviation:  Ophthal Plast Reconstr Surg     Publication Date:    2011 Jul-Aug
Date Detail:
Created Date:  2011-07-12     Completed Date:  2011-09-21     Revised Date:  2013-06-21    
Medline Journal Info:
Nlm Unique ID:  8508431     Medline TA:  Ophthal Plast Reconstr Surg     Country:  United States    
Other Details:
Languages:  eng     Pagination:  e87-8     Citation Subset:  IM    
Affiliation:
Massachusetts Eye and Ear Infirmary, Boston, Massachusetts 02142, USA. borodic@aol.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antibodies, Monoclonal / adverse effects*
Antigens, CD / drug effects*
Antineoplastic Agents / adverse effects*
CTLA-4 Antigen
Diplopia / chemically induced
Exophthalmos / chemically induced
Female
Graves Ophthalmopathy / chemically induced*
Humans
Lung Neoplasms / drug therapy,  secondary
Magnetic Resonance Imaging
Melanoma / drug therapy,  secondary
Middle Aged
Neoplasms, Unknown Primary / drug therapy,  pathology
Oculomotor Muscles / drug effects
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antigens, CD; 0/Antineoplastic Agents; 0/CTLA-4 Antigen; 0/CTLA4 protein, human; 0/ipilimumab
Comments/Corrections
Comment In:
Ophthal Plast Reconstr Surg. 2013 May-Jun;29(3):239-40   [PMID:  23652294 ]
Ophthal Plast Reconstr Surg. 2013 May-Jun;29(3):241   [PMID:  23652295 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Preoperative Radiation Therapy in the Management of Recurrent Orbital Hemangiopericytoma.
Next Document:  Densities of Orbital Fat and Extraocular Muscles in Graves Orbitopathy Patients and Controls.